Insider Ledger
NovaBridge Biosciences (NBP) insider buying and SEC filings
NovaBridge Biosciences · CIK 1778016
Tracked: Forms 3/4/5, 8-K, NT · Limited coverage: files 6-K/20-F, not covered in v1 · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- E9
- Fiscal year end
- Dec 31
- Former names
- I-Mab
Insider activity in the last 12 months
Bought
$577K
Insiders who bought
1
Sold (not marked 10b5-1)
$154K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 18, 2026 | Sale | Phillip Andrew Dennis (Chief Medical Officer) sold 8,209 shares at $0.7100 ($6K). Holdings down 5% to 173,427 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 21, 2026 |
| Sep 9, 2026 | Sale | Sean Wuxiong Cao (Chief Bus. Development Officer) sold 107,978 shares at $0.7400 ($80K). Holdings down 29% to 266,467 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 11, 2026 |
| Aug 31, 2026 | Sale | Cong Claire Xu (EVP, Clinical Development) sold 3,282 shares at $0.7900 ($3K). Holdings down 1% to 304,201 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 1, 2026 |
| Jul 6, 2026 | Sale | Cong Claire Xu (SVP, Clinical Development) sold 4,485 shares at $0.8900 ($4K). Holdings down 1% to 298,101 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 7, 2026 |
| Jun 18, 2026 | Sale | Phillip Andrew Dennis (Chief Medical Officer) sold 8,494 shares at $0.6600 ($6K). Holdings down 5% to 157,941 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 22, 2026 |
| Jun 1, 2026 | Sale | Cong Claire Xu (SVP, Clinical Development) sold 3,494 shares at $3.94 ($14K). Holdings down 1% to 290,154 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 2, 2026 |
| May 14, 2026 | Sale | Sean Wuxiong Cao (Chief Business Development Officer and Director) sold 21,399 shares at $1.99 ($43K). Holdings down 38% to 35,073 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 18, 2026 |
| Apr 24, 2026 | Purchase (code P) | Mark Arnold Hagler (President / COO) bought 230,000 shares at about $2.51 ($577K), reported as a purchase (code P). New position of 230,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 28, 2026 |
13 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow NBP in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.